First human test of new Alzheimer's vaccine begins
NCT ID NCT05642429
Summary
This early-stage study is testing the safety of an experimental vaccine called AV-1959D in people with early Alzheimer's disease. The trial will enroll 48 participants aged 60-85 to see how well they tolerate different doses and to measure their immune response. The main goal is to identify any side effects before testing whether the vaccine can help slow or control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Accel Research
Decatur, Georgia, 30033, United States
-
Alzheimer's Research and Treatment Center
Wellington, Florida, 33414, United States
-
Banner Alzheimer's Institute
Phoenix, Arizona, 85006, United States
-
Global Medical Institutes Princeton Medical Institute
Princeton, New Jersey, 08540, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
University of South Florida
Tampa, Florida, 33613, United States
Conditions
Explore the condition pages connected to this study.